The quest for a 'one-and-done' flu shot has taken a major leap forward with successful Phase 2 trials of a universal influenza vaccine based on mRNA technology.
Targeting the Conserved 'Stalk'
Traditional flu shots target the 'head' of the hemagglutinin protein, which mutates rapidly (requiring annual updates). This new vaccine directs the immune system to attack the protein's 'stalk'—a structural foundation that rarely changes across different flu strains.
Broad Protection
Trial participants showed robust antibody responses not just to the specific flu strain in the vaccine, but to distinct strains they had never been exposed to. This 'cross-protection' persisted for at least three years in follow-up studies.
Pandemic Prevention
Beyond convenience, this vaccine is a biosecurity shield. It would provide immediate baseline protection against novel pandemic flu strains jumping from animals to humans (like H5N1), buying time for specific boosters.
Regulatory Path
Phase 3 trials involving 30,000 people are launching globally. If successful, the universal vaccine could replace the seasonal shot by 2028, potentially eradicating seasonal flu epidemics.
